Rheumatoid Arthritis

Exagen studies 192 established RA pts (383 controls) for Abs: CCP2, RF IgA, RF IgM, PAD4 (IgA, IgG). RA signif assoc w/ CCP2+ (OR 110), RF (>7), PAD4 (3.5-5.9). In CCP neg - only PAD4 IgG (2.87) & RF (2.2) assoc w/ RA, w/ only small Dx gain (ΔAUC 0.02–0.04). https://t.co/isf7aMf24O

Article

Pregnancy in Lupus Nephritis and RA: Managing risks and treating to target

Sheila Reyes, MD Nov 03, 2026

A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern rheumatology care.

Same molecule, different route, different persistence: golimumab IV persisted 4.44 yrs vs 2.07 for SC in biologic-naive RA (n=9,464, Korean claims). Is it the route, or differenntial out of pocket cost, or supervised dosing and better adherence? P#240 #APLAR26 @RheumNow

Older adults with RA on JAKi: filgotinib may carry a lower zoster risk than others. Is it JAK1 selectivity? UPA (available in the US) is also selective. Dose, zoster vaccination status and a mixed comparator group may matter. Day 3 Abst Session 7 #APLAR26 @RheumNow https://t.co/5ri4shAHnV

Raychaudhuri (day 2 plenary): Reconceptualizing cells as continuous states, not discrete types. In RA synovium, AMP defined six inflammation patterns (CTAPs) with key cell states, e.g. Tph in T+B. Do CTAPs respond to different targets? #APLAR26 @RheumNow https://t.co/jIosTqv5qZ

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/xTlr5lrwUz

T cell clone in AxSpA Trvb9 & Trav 21 B27 pos pts - t cell engager developed @RheumNow #APLAR2026 https://t.co/Jt7XBu3Kok

https://x.com/drpnash/status/2116405424090153127/photo/1

Article

Mixed Drinks, Mixed Results (10.30.2026)

Jack Cush, MD Oct 30, 2026

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis

number of naive-like CAR-T infused associates with prolonged survival but highly variable APLAR Seoul 2026 #CAR-T #Rheum Now

Georg Schett : cure prime goal of therapy! remission off all treatment , APLAR Seoul 2026 #CART #RheumNow https://t.co/kygOGdxUSe

https://x.com/drpnash/status/2115698926141726949/photo/1

“Complex to manage” in SLE not for biologics APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/4qeRGEVijs

https://x.com/drpnash/status/2115998694860574864/photo/1

Artiva has stopped development of its AlloNK (allogeneic NK cell therapy) after 2 reported deaths in their phase II RCT in #RA and other autoimmune conditions. Artiva has suspended its phase III trial with AlloNK. https://t.co/mLR6xciRfB https://t.co/mv2m8rhst6

Artiva to quit autoimmune cell therapy work, cut staff after patient deaths

Mark your calendar: RheumNow is covering ACR Convergence 2026, beginning November 7th! Follow along for clinical trial highlights, expert perspectives, daily faculty recaps, livestreams and more. Visit https://t.co/ofGKCCNQnE for the latest coverage. #ACR26 #Rheumatology https://t.co/5p5UxMLu51

Home | RheumNow

Article

Menopause Hormone Therapy Tied to Small Autoimmune Disease Risk

MedPage Today Oct 27, 2026

Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested.

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/jQQGzhAm7c

Treat-to-Target has Excellent 10-Year Outcomes in RA Most patients with RA whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. https://t.co/aWQgQAsoSI

Cryptococcus is rare, but twice as likely with JAK inhibitors. Retrospective TriNetX analysis of RA pts (>30k/grp) starting JAKi vs TNFi; JAKi vs non-TNFi; & TNFi vs non-TNF. Crypto seen in <0.2% in all groups; but signif higher HR for JAKi (HR 2.2 & 2.15) https://t.co/1J4SjcqF8u

Biologic safety. Vasculitis mimics. What to do with seropositive arthralgia. RheumNow Live 2027 tackles the decisions you face in clinic. Jan. 30–31 | Onsite + virtual Registration NOW OPEN. Early Bird Pricing through 12/15/2026. https://t.co/zYYC2350tE https://t.co/mPI1o7sEcx

RheumNow

Joint Disease in SLE Reconsidered A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may https://t.co/M5m6TMZr3x

Article

Double Trouble (10.23.2026)

Jack Cush, MD Oct 23, 2026

Dr. Jack Cush reviews the journal articles and regulatory announcements from this past week on RheumNow, including: two crystals in one joint, twice the cryptococcus risk in JAKs; Myositis and Scleroderma; and Sjögren’s plus early damage = >> 2 fold risk lymphoma. Double trouble week

Tis the Season for Vaccination Vaccination is essential for all rheumatologic patients, but particularly for patients on glucocorticoids and immunosuppression who face increased risk from infectious diseases. https://t.co/hHx1okkwHD https://t.co/nzRa9pzQ1X

‘Tis the Season for Vaccination | RheumNow

Article

Treat-to-Target has Excellent 10-Year Outcomes in RA

MedPage Today Oct 21, 2026

Most patients with rheumatoid arthritis (RA) whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said.

Cryptococcus is rare, but twice as likely with JAK inhibitors. Retrospective TriNetX analysis of RA pts (>30k/grp) starting JAKi vs TNFi; JAKi vs non-TNFi; & TNFi vs non-TNF. Crypto seen in <0.2% in all groups; but signif higher HR for JAKi (HR 2.2 & 2.15) https://t.co/fJeKwDZABL

Polish study compared comorbidities #s in incident RA & PsA. RA pts were older at dx (61 vs 44 yrs) & may drive higher rates in RA. 23/3 comorbidities (74%) were signif more prevalent in RA, including HTN (18 v 12%), ischemic HD (11 v 6%), cerebrovascular dz (4 vs 2%) https://t.co/l0RW6bVVHd

No difference in MACE risk betw TNFi vs JAKi in 6174 RA pts. Korean claims data compared TNFi (n 5,152) vs JAKi (n 1,022) initiators. MACE risk was 4.1 & 3.6/1000PYs w/ TNFi vs JAKi, respectively. MACE risk did not differ significantly between JAKi and TNFi (adj HR 0.636; 0.283, https://t.co/035WSUQAhJ